| Trial-Results center | |||
| Clinical trial results database |
 Feedback
 Home
|
Systematic review and meta-analysis
This trial is included in the following systematic reviews and meta-analyses:
atrial fibrillation
-
antithrombotics
-
primary prevention of thromboembolic events
atrial fibrillation
-
new anticoagulants
-
all type of patients
Related trials
AVERROES, 2011 - apixaban vs aspirin
ROCKET-AF, 2010 - rivaroxaban vs warfarin standard dose
EXPLORE-Xa, 2010 - betrixaban vs warfarin standard dose
RE-LY (110mg), 2009 - dabigatran 110mg vs warfarin standard dose
Lip (phase 2 AZD0837), 2009 - AZD0837 vs warfarin standard dose
ACTIVE A, 2009 - aspirin + clopidogrel vs aspirin
RE-LY (150mg), 2009 - dabigatran 150mg vs warfarin standard dose
AMADEUS, 2008 - idraparinux vs warfarin standard dose
PETRO (150mg), 2007 - dabigatran 150mg vs warfarin standard dose
ACTIVE W, 2006 - aspirin + clopidogrel vs anticoagulant
SPORTIF V, 2005 - ximelagatran vs warfarin standard dose
NASPEAF (triflusal vs coumadin standard dose)), 2004 - triflusal vs coumadin standard dose
SPORTIF III, 2003 - ximelagatran vs warfarin standard dose
SPORTIF II (ximelagatran vs warfarin standard dose), 2002 - ximelagatran vs warfarin standard dose
PATAF (vs coumadin standard dose), 1999 - aspirin vs coumadin standard dose
PATAF (vs coumadin low dose), 1999 - aspirin vs coumadin low dose
MWNAF, 1998 - warfarin low dose vs warfarin standard dose
AFASAK II (aspirin vs warfarin low dose), 1998 - aspirin vs warfarin low dose
AFASAK II (aspirin vs warfarin standard dose), 1998 - aspirin vs warfarin standard dose
SPAF III, 1996 - warfarin + aspirin vs warfarin standard dose
See also:
phase 2 dabigatran study, 0 |
|
| [NCT01136408] unpublished (or not yet fully published) trial Preliminary results |
Tweet
Facebook
 pdf :
dabigatran
-
antithrombotics for atrial fibrillation
|
Treatments
| Studied treatment |
Dabigatran 110, 220, 300 mg twice daily
|
| Control treatment |
warfarin
|
Patients
| Patients | patients with non-valvular atrial fibrillation (paroxysmal, persistent or permanent) |
| Inclusion criteria | 1) Hypertension; 2) Diabetes mellitus; 3) Left-side heart failure; 4) A previous ischemic stroke or transient ischemic attack; 5) Age 75 years or older; 6) history of coronary artery diseases; |
Method and design
| Randomized effectives | NA / NA (studied vs. control) |
| Design | Parallel groups |
| Blinding | open |
| Geographic area | Japan |
| Primary endpoint | major bleeding event, , |
| Studied endpoints | Incidence of major bleeding event, Incidence of clinically relevant bleeding event, Incidence of nuisance bleeding event, A composite clinical endpoint including the incidence of ischemic or haemorrhagic stroke (fatal or non-fatal), transient ischemic attacks, systemic embolism, myocardial infarction (fatal or non-fatal), other major adverse cardiac events, and death, The incidence of ischemic or haemorrhagic stroke (fatal or non-fatal), The incidence of transient ischemic attack, The incidence of systemic embolism, The incidence of myocardial infarction (fatal or non-fatal), The incidence of other major adverse cardiac events, The incidence of death, |
Results
No results available for this trial - unpublished or not fully published trial
Meta-analysis of all similar trials:
antithrombotics in atrial fibrillation for primary prevention of thromboembolic events
new anticoagulants in atrial fibrillation for all type of patients
Reference(s)
| Trials register # | NCT01136408 |
unpublished (or not yet fully published) trial
(c) 2004-2011 TrialResults-center - All Rights Reserved
Tweet this
notify a friend